A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Sponsor
Addpharma Inc.
Study ID
NCT07590167
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • AD-231 — DRUG
    AD-231 Oral Tablet
  • AD-231A, AD-231D and AD-231C — DRUG
    AD-231A Oral Tablet + AD-231D Oral Tablet + AD-231C Oral Tablet

Study Details

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Key Dates

First listed
May 15, 2026
Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Sequence A (RT)
    Period 1: Reference Drug(AD-231A, AD-231D and AD-231C), Period 2 : Test Drug(AD-231)
  • Experimental: Sequence B (TR)
    Period 1: Test Drug(AD-231), Period 2 : Reference Drug(AD-231A, AD-231D and AD-231C)

Primary Outcome Measure

Maximum concentration of drug in plasma (Cmax) [ Time Frame: pre-dose to 72 hours ]

Central Contacts

Find similar trials

Nationwide
Hypertension (high blood pressure) trialsCardiology trialsHeart disease trials

Related Studies